We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





First FDA EUA COVID-19 Saliva Testing Kits Launched

By LabMedica International staff writers
Posted on 04 Aug 2020
The first FDA Emergency Use Authorization (EUA) COVID-19 saliva testing kits have been launched in the US by Accumen Inc. More...
(Phoenix, AZ, USA) in partnership with Spectrum Solutions (Salt Lake City, UT, USA).

Saliva testing for detecting COVID-19 first received FDA EUA in April. This authorization mandated saliva collection solely using Spectrum’s SDNA-1000 saliva collection device based on a trial with Rutgers University. The Spectrum saliva collection kit has been engineered to produce more accurate and sensitive test results, reduce sample collection errors, including for at-home self-collection, reduce labor required for collection and reduce use of valuable PPE.
Additionally, the SDNA-1000 delivers 100% neutralization of the live virus mitigating risk and the threat of unnecessary exposure. It can also preserve and stabilize viral RNA transcripts for transport in extreme and varying temperatures for more than 14 days and for up to one-year post collection in ambient storage.

Accumen is offering the full kit or only the saliva collection device, as well as implementation support services. In addition to COVID-19 saliva testing kits, the company is also offering 3D-printed COVID-19 testing swabs, face shields and disposable masks, gowns, and gloves. For healthcare providers and institutions that need immediate access to other COVID-19-related resources, Accumen provides laboratory, imaging, blood management rapid response tools and other strategic pandemic resources.

“Accumen has been partnering with its clients to strengthen their laboratory supply chain for more than 10 years. Early in the COVID-19 crisis, we identified supply chain gaps and began coordinating resources to meet those evolving needs. As the crisis continued, we were able to provide critical testing supplies like nasopharyngeal (NP) swabs, media and personal protective equipment (PPE) for our clients, and we later made those resources available to other health systems and laboratories across the country to help increase testing efforts,” said Eric Jurinic, Accumen Vice President of Corporate Supply Chain.

Related Links:
Accumen Inc.
Spectrum Solutions



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Automated Immunoassay Analyzer
SuperFlex™
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.